#TranslationalPharmaceutics® has been a core part of #QuotientSciences’ approach for nearly two decades. Download our recently updated info sheet to learn more about how it works to accelerate drug programs: https://bit.ly/4iH9JqI
Quotient Sciences
Pharmaceutical Manufacturing
Nottingham, Nottinghamshire 21,632 followers
Molecule to cure. Fast.
About us
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast. We employ over 1,300+ staff and operate from state-of-the-art manufacturing and clinical facilities in the US and UK. Our people make Quotient Sciences a special place to work. We are a dedicated team passionate about innovating and transforming drug development to help our customers develop new medicines for patients in need. We recruit people that are committed to making a difference, who excel at customer service and are always willing to go the extra mile. Teamwork is integral to our culture and success — helping, supporting and mentoring run through our DNA. Expect to join an empowering and innovative culture, where we encourage continuous improvement and offer opportunities to learn and develop every day.
- Website
-
https://bit.ly/3u9sI6l
External link for Quotient Sciences
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- Nottingham, Nottinghamshire
- Type
- Privately Held
- Specialties
- CDMO, Formulation Development, Phase I & II Clinical Trial Manufacturing, Translational Pharmaceutics, High Potency Handling, Real-time Adaptive Manufacturing, Commercial Manufacturing, Solubility Enhancement, Modified Release, Pediatric Formulation Development, CRO, First-in-Human, Clinical Pharmacology, Relative Bioavailability, Pharmacokinetics, Drug-Drug Interaction, Human ADME / 14C, Data Sciences, Modelling & Simulation, Drug Substance, Scintigraphy, Bioanalysis, Isotope Labelling, Clinical Trial Supplies, Bioequivalence, Healthy Volunteer Studies, Proof-of-Concept, Drug Development, and Dosage Form Development
Products
Locations
Employees at Quotient Sciences
Updates
-
That's a wrap on a successful week at #DCAT in New York City! Our team enjoyed meeting and connecting with everyone at the event! If you weren't able to attend or missed us there, learn more about our innovative service offerings and extended capabilities today: https://bit.ly/3Mm5HpW #DCATWeek2025 #QuotientSciences
-
-
Yesterday, our team attended the 2025 #CDMOLeadershipAwards in New York City. We are proud to share that #QuotientSciences has been named a winner in the category of Small Molecule Dosage Form - Global. This recognition is a testament to the unwavering dedication of our teams in providing innovative, quality services while accelerating #drugdevelopment timelines. https://bit.ly/4kjcP5I
-
-
The UK’s strong scientific and medical expertise makes it a top choice for early phase research. In this article, Dr. Kate Darwin, Vice President of Regulatory Affairs, explains UK timelines for trial approval and why the UK remains a great place to do Phase I trials: https://bit.ly/4inX4ZZ
-
-
#DCAT week is off to a great start! Yesterday, Brad Rowe, Senior Director of Integrated Development, and Robert Cornog, Senior Director of Product Development, led an insightful seminar discussing CMC strategies to manage the risks associated with accelerated submission pathways. It was great connecting with all who attended! If you haven't had a chance to connect with us at the event yet, there's still time to meet with our team! Additionally, we will be hosting another seminar this afternoon, led by Dr. Vanessa Zann, VP of Scientific Consulting, Translational Pharmaceutics® and Clinical Pharmacology USA. Learn more: https://bit.ly/3FDX21D
-
-
Latest news: #QuotientSciences has been recognized as a finalist for a special category award, Best Innovative Approach to Technology and Process Execution, in the 2025 #CDMOLeadershipAwards. This award nomination highlights our unwavering commitment to providing innovative solutions and exceptional service within the #CDMO sector. Stay tuned as the official awards will be announced tomorrow. https://bit.ly/4kxw37Z
-
-
In our latest article, learn about our #clinicalpharmacology work assessing the #firstinhuman safety, tolerability, #pharmacokinetics, and pilot food-effect study of the candidate antimalarial compound MMV367. Read more: https://bit.ly/4kN6YWF
-
-
In our latest article, learn about our #clinicalpharmacology work assessing the #firstinhuman safety, tolerability, #pharmacokinetics, and pilot food-effect study of the candidate antimalarial compound MMV367. Read more: https://bit.ly/4kN6YWF
-
-
Dedicated to adaptive early phase clinical trials and drug development, #QuotientSciences can help accelerate your molecule from first-in-human to proof of concept. We are focused on delivering the insight you need to design and deliver your #clinicalpharmacology program with confidence. Learn more about how our fully integrated approach ensures seamless execution and high-quality results, delivered safely and rapidly: https://lnkd.in/e3nTSReW
-
Don't miss our upcoming #seminar happening next month in Boston, MA! Led by Brad Rowe, Senior Director of Integrated Development, and Robert Cornog, Senior Director of Product Development, this event will cover CMC strategies to manage the risks associated with accelerated submission pathways, up to and including the scale-up and #commercialmanufacturing of #drugproducts. Register today: https://bit.ly/4hvi3c1
This content isn’t available here
Access this content and more in the LinkedIn app